Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1213-1222

  Molife, L Rhoda ^a   Rudman, Sarah M ^b   Alam, Salma ^a   Tan, Daniel S W ^a   Kristeleit, Hartmut ^b   Middleton, Gary ^c   Propper, David ^d   Bent, Liz ^e   Stopfer, Peter ^f   Uttenreuther Fischer, Martina ^f   Wallenstein, Gudrun ^f   De Bono, Johann ^a,g   Spicer, James ^b,h  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e BOEHRINGER INGELHEIM LTD   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antitumor activity; Cardiac safety; ErbB family blocker; Pharmacokinetics; Solid tumors

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACNE; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; BLOOD SAMPLING; BRAIN METASTASIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL TUMOR; CONJUNCTIVITIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; ELECTROCARDIOGRAM; EPISTAXIS; ESOPHAGUS TUMOR; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GLIOBLASTOMA; HAND FOOT SYNDROME; HEART RATE VARIABILITY; HEART REPOLARIZATION; HUMAN; LIVER TUMOR; LOWER RESPIRATORY TRACT INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS TUMOR; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; QT INTERVAL CORRECTED BY THE FRIDERICIA FORMULA; SINGLE DRUG DOSE; SMALL INTESTINE TUMOR; SOLID TUMOR; STEADY STATE; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84890317176     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2286-7     Document Type: Article

References (35)

1. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
2. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
3. Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350
4. Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711
5. Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387
6. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-370
7. Lin NU, Winer EP, Wheatley D et al (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133:1057-1065
8. Miller VA, Hirsh V, Cadranel J et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:528-538
9. Yang JCH, Shih JY, Su WC et al (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13:539-548
10. Sequist LV, Yang JCH, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334
11. Yap TA, Vidal L, Adam J et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972
12. Yang JCH, Hirsh V, Schuler M et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3342-3350
13. Mehra R, Ang KK, Burtness B (2012) Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 22:194-197
14. FDA label for Lapatinib - revised: March 2007
15. Morganroth J, Shah RR, Scott JW (2010) Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarisation (QTc Interval). Nature 87:166-174
16. Lee HA, Kim E-J, Hyun SA et al (2010) Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarisation. Basic Clin Pharmacol Toxicol 107:614-618
17. Rock EP, Finkle J, Fingert HJ et al (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827-836
18. Liu Q, Madabushi R, Garnett C, Booth B (2008) Experience in QT evaluation of oncology drug products since ICH E14 guidance [abstract]. J Clin Oncol 26(Suppl):2554
19. Trani L, Alam SM, Molife LR et al (2010) A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 28(Suppl. 15):TPS187
20. Carden CP, Agarwal R, Saran F et al (2008) Eligibility of patients with brain metastases for phase I trials: time for a rethink? Lancet Oncol 9:1012-1017
21. Papadatos-Pastos D, Banerji U (2011) Revisiting the role of molecular targeted therapies in patients with brain metastases. J Neurooncol 105:467-474
22. ICH E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (ICH harmonized tripartite guideline, recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee). Available from URL: http://www.fda.gov/ downloads/RegulatoryInformation/Guidances/ucm129357.pdf
23. Stopfer P, Marzin K, Narjes H et al (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051-1061
24. Eskens F, Mom CH, Planting AST et al (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80-85
25. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 (Aug. 9, 2006)
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
27. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
28. Hug B, Abbas R, Leister C et al (2010) A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res 16:4016-4023
29. Center for Drug Evaluation and Research Approval Package for: Application Number 21-743, Clinical Pharmacology and Biopharmaceutics Review. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21-743-Tarceva- biopharmr.PDF
30. Dasanu CA, Padmanabhan P, Clark BA 3rd et al (2012) Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Expert Opin Drug Saf 11:445-457
31. Perez EA, Koehler M, Byrne J et al (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83:679-686
32. electronic Medicines Compendium (eMC). Tyverb: summary of product characteristics [Date of revision of text 19 October 2012]. Available from URL: http://www.medicines.org.uk/emc/medicine/20929/SPC/tyverb
33. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231-2247
34. FDA label for Iressa (gefitinib) - Revised April 2004
35. Finkle J, Bloomfield D, Uhl K et al (2009) New precompetitive paradigms: focus on cardiac safety. Am Heart J 157:825-826